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http://dx.doi.org/10.1016/j.kjms.201Abstract There are clear discrepancies between ethnicity and geographic area regarding the
peak age incidence and mortality of breast cancer. Underlying variances include genetic, envi-
ronmental, and socioeconomic factors. The wild-type p53 codon has two common polymorphic
variants from a single-base-pair substitution at codon 72, where either C-C-C encodes proline
(p53-p72) or C-G-C encodes arginine (p53-R72). We aim to study the p53 codon 72 genotypes of
patients with breast cancer in Taiwan and make a comparison with the published data to ascer-
tain whether any difference exists between Taiwanese and Western patients with breast
cancer. We also evaluated the effect of the p53 codon 72 polymorphism on clinicopathologic
features. We examined blood from 170 Taiwanese women with breast cancer with polymerase
chain reactionerestriction fragment length polymorphism for the genotypes of p53 codon 72.
For the p53 codon 72 polymorphism, there were 31 p53-P/P72 (18.2%), 93 p53-R/P72 (54.7%),
and 46 p53-R/R72 (27.1%) with the allele frequencies 0.54 for the p53-R72 and 0.46 for p53-
P72, respectively. Our results indicate that there was more p53-P72 (40.6% in Asians vs.
26.4% in Caucasians) and twice the incidence of p53-P/P72 homozygotes (18% in Asians vs.
8% in Caucasians) among the Asian population. Patients with the p53-R/R72 variant were moreof Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan
u.tw (M.-F. Hou).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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260 F.-M. Chen et al.likely to have a t1 tumor size status (55.2%) compared with patients with the P53-P/R72
(30.9%) or P53-P/P72 variant (36%). Our results support the hypothesis that genetic factors
may contribute to the difference between Taiwanese or Asian breast cancer and Western
breast cancer patient populations.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Among Taiwanese women, breast cancer is the most
common form of malignancy and the fourth leading cause
of cancer-related death. In 2008, death rates in females
from breast cancer were 11.33 per 100,000 people [1]. The
risk factors of getting breast cancer in Taiwan, which is
a low-incidence area, are similar to those in high- to
moderate-risk areas. Family history and the effects of
reproductive hormones play the most significant role [2,3].
However, when compared with the number of breast cancer
cases in Western countries, the peak of the age-specific
incidence rates appeared 10e20 years earlier and the
age-specific mortality rates peaked at ages 55e59 years and
after age 80 years in Taiwan [1,4]. These divergences may
be due to multiple factors including racial/ethnic back-
ground and genetic variation [5].
p53, the most frequent genetic event among the tumor
suppressors [6,7], exerts a protective response either by
regulating the cell cycle at the G1/S checkpoint for DNA
repair [8] or by inducing apoptosis in genetically damaged
cells [9]. Recently a single nucleotide polymorphism (SNP)
of either C-C-C encoding proline (p53-P72) or C-G-C
encoding arginine (p53-R72) [10] at codon 72 of the p53
gene has been extensively studied, not only because of its
significant implication in carcinogenesis but also for its
clinical controversies. The SNP is located in a proline-rich
region (residues 64e92) of the p53 protein, where the
p53-P72 amino acid constitutes one of five PXXP motifs that
resembles a SH3-binding domain and is required for the
growth suppression and apoptosis mediated by p53 [11]. In
1998, Storey et al. [12] showed the unprecedented finding
that the E6 proteins from human papilloma virus (HPV)
types are able to target p53-R72 more efficiently than
p53-P72 for ubiquitin-mediated degradation. They also
demonstrated that p53-R/R72 homozygotes are approxi-
mately seven times more susceptible to HPV-associated
tumorigenesis than heterozygotes. The arginine-encoding
allele therefore represents a significant risk factor in the
development of HPV-associated cancers [12]. Although
subsequent studies further supported the biologic contri-
bution of the codon 72 polymorphism in tumorigenesis
[13e17], the significance of the p53 codon 72 polymorphism
remains controversial with regard to cancer susceptibility
because of the inconsistency of the association between
the polymorphism and the cancer risk [16,18e20] or prog-
nosis [20,21] in different cancer types. In breast cancer,
p53-R72 has been suggested as a susceptibility allele,
especially in Europeans [17,22]. However, p53-P/P72
homozygosity has also been associated with increased
breast cancer risk [17,23]. Studies against the association of
the p53-R72P polymorphism and breast cancer risk havealso been reported [24]. Furthermore, either P53-P/P72
homozygous or retention of the arginine allele in the tumor
tissue of p53-R/P72 in patients with heterozygous breast
cancer was recently identified as an independent prog-
nostic marker [25,26]. Recent work has also provided
evidence that p53 codon 72 polymorphism may modulate
the response to cancer therapy [27e29].
The distribution of p53 codon 72 polymorphism as well as
the association of this polymorphism with breast cancer
features remains undefined in Taiwan, which has a non-
Caucasian population with low breast cancer risk. Here we
genotyped the p53 codon 72 polymorphism using restriction
fragment length polymorphism and compared our geno-
types with published results to test if the difference of
genotypes exists between different areas.
Methods
Specimen collections
In the current study, blood samples obtained from 170
patients with primary breast cancer who underwent surgery
at the Department of Surgery of Kaohsiung Medical
University Hospital (KMUH) between February 2003 and
February 2007 were analyzed for p53 codon 72 genotyping.
This study protocol was approved by the Institutional
Review Board of KMUH and informed consent was obtained
from each participant. None of the patients had undergone
radiotherapy or chemotherapy before surgery. The tumor
tissues were sent for routine histopathologic diagnosis,
including an HER2 expression study according to the usual
criteria at the KMUH, as described previously [30]. Blood
samples from control patients without cancer (in a 1:2
ratio) were collected for comparison of the distribution of
p53 codon 72 polymorphism with cancer patients.
DNA extraction and p53 codon 72 genotyping
DNA was extracted from the buffy coat using a commercial
kit (QIAGEN, Hilden, Germany). Genotyping was performed
using the polymerase chain reaction (PCR)erestriction
fragment length polymorphism method, with the digested
PCR products applied to electrophoresis on agarose gels,
and viewed using ethidium bromide. The following primers
were used: forward primer 50-TAATACGACTCACTATAGG
GCCGTCCCAAGCAATGGATGAT-30 and reverse primer 50-CT
GGGAAGGGACAGAAGATGA-30. PCR was obtained in a 15-mL
reaction mixture containing 100 ng of genomic DNA
template, 2 mL 10PCR buffer, 0.8 mmol/L deoxynucleo-
tide triphosphate, 2.5 mmol/L MgCl2, 0.5 mmol/L primers,
and 1 unit mpliTaq DNA polymerase (Promega, Madison, MI,
Table 1 Patients’ characteristics and clinicopathologic
features and p53 codon 72 polymorphism.
Total,
n
RR,
n (%)
RP,
n (%)
PP,
n (%)
p
Menopausal status
Premenopausal 59 14 (30.8) 31 (34.2) 14 (41.4) 0.655
Postmenopausal 111 32 (69.2) 62 (65.8) 17 (58.6)
Tumor histology
Ductal 129 34 (94.4) 69 (95.8) 26 (86.7) 0.406
Lobular 9 2 (5.6) 3 (4.2) 4 (13.3)
Tumor size
t1 46 16 (55.2) 21 (30.9) 9 (36) 0.046
t2þt3þt4 76 13 (44.8) 47 (69.1) 16 (64)
Lymph node
0 82 23 (62.2) 45 (57.7) 14 (48.3) 0.676
1e3 42 8 (21.6) 24 (30.8) 10 (34.5)
4 20 6 (16.2) 9 (11.5) 5 (17.2)
Stage
0 20 7 (18.9) 9 (11.8) 4 (13.8) 0.475
I 38 11 (29.7) 19 (25) 8 (27.6)
II 58 12 (32.5) 37 (48.7) 9 (31.0)
III 26 7 (18.9) 11 (14.5) 8 (27.6)
ER status
Negative 45 15 (38.5) 23 (32.4) 7 (29.2) 0.715
Positive 89 24 (61.5) 48 (67.6) 17 (70.8)
PR status
Negative 53 17 (43.6) 28 (39.4) 8 (33.3) 0.721
Positive 81 22 (56.4) 43 (60.6) 16 (66.7)
Her2/neu
Negative 59 13 (33.3) 35 (49.3) 11 (45.8) 0.267
Positive 75 26 (66.7) 36 (50.7) 13 (54.2)
ER Z estrogen receptor; PR Z progesterone receptor.
p53 codon 72 polymorphism 261USA). The reaction conditions used were initial denatur-
ation at 94C for 2 minutes, followed by 35 step-cycles of
denaturation at 94C for 30 seconds, annealing at 60C for
45 seconds, and extension at 72C for 30 seconds followed
by a terminal extension time of 10 minutes. Ten microliters
of PCR product were digested with BstU1 restriction
enzyme (New England Biolabs, Inc., Ipswich, MA, USA) for
12 hours at 60 C. The digestion products were then
resolved on a 2.5% agarose gel containing ethidium
bromide. As shown in Fig. 1, the p53-P/P72 variant was
identified by a single band (195 bp), the p53-R/R72 variant
produced two bands (85 bp and 110 bp), and the hetero-
zygous p53-R/P72 variant displayed three bands (195, 85,
and 115 bp).
Statistical analysis
All data were analyzed using the Statistical Package for the
Social Sciences Version 11.0 software (SPSS Inc., Chicago,
IL, USA). The two-sided Pearson c2 test was used to
compare the clinicopathologic parameters with p53 codon
72 genotypes. A probability of less than 0.05 was consid-
ered to be statistically significant.
Results
In our study, 170 patients with breast cancer without
selection of age or family history were enrolled. The mean
age (standard deviation) for patients with breast cancer
was 52.3 (17.7). There were 20 intraductal carcinomas,
122 infiltrating ductal carcinomas, 17 infiltrating lobular
carcinomas, three medullary carcinomas, three tubular
carcinomas, three mucinous carcinomas, and two atypical
medullary carcinomas. The clinicopathologic characteris-
tics and the frequencies of the three p53 genotypes p53-R/
R72, p53-R/P72, and p53-P/P72 are summarized in Table 1.
Due to the inadequacy of tumor tissue or missed data, the
complete clinicopathologic data were not obtained for
every patient. The frequencies of p53-R/R72, p53-R/P72,
and p53-P/P72 found in the patients with breast cancer in
Taiwan were 27.1% (46 of 170), 54.7% (93 of 170), and 18.2%
(31 of 170), respectively. The clinicopathologic features
including tumor size, nodal involvement, grading, estrogen
receptor (ER), progesterone receptor (PR), and HER2
expression were evaluated. No significant differences in theFigure 1. The p53-P/P72 variant was identified by a single
band (195 bp), the p53-R/R72 variant produced two bands
(85 bp and 110 bp), and the heterozygous p53-R/P72 variant
displayed three bands (195, 85, and 115 bp).distribution of clinicopathologic parameters between p53-
R72 and p53-P72 patients were found except for tumor
size. Patients with the P53-R/R72 variant were more likely
to have a t1 tumor size status, compared with patients with
the P53-P/R72 or P53-P/P72 variant. In the P53-R/R72
group, 55.2% of patients (16 of 29) were of t1 status
compared with 30.9% or 36% of patients (21 of 68 and 9 of
25, respectively) in the P53-P/R72 or P53-P/P72 groups,
respectively (p Z 0.046). Genomic DNA from patients with
breast cancer and control patients without cancer (in the
1:2 ratio) was analyzed to compare the distribution of p53
codon 72 polymorphism. Overall, there was no difference in
genotype distributions between control patients without
cancer and patients with breast cancer (data not shown).
Discussion
Among the 170 breast cancer cases we genotyped, there
were 31 p53-P/P72 (31 of 170, 18.2%), 93 p53-R/P72 (93 of
170, 54.7%), and 46 p53-R/R72 (46 of 170, 27.1%), respec-
tively. The allele frequencies were 0.54 for the p53-R72
and 0.46 for p53-P72 with the polymorphism in Hardy-
Weinberg equilibrium. Among the analyzed clinicopatho-
logic characteristics, we observed a statistically significant
262 F.-M. Chen et al.association between the p53 codon 72 genotypes and tumor
size but not with any other characteristics such as meno-
pausal status, histologic type, tumor size, lymph node
status, or histologic grade (Table 1). In addition, 55.2% of
patients (16 of 29) with p53-R/R72 genotype had a t1 status
compared with 30.9% or 36% of patients (21 of 68 and 9 of
25, respectively) in the P53-P/R72 or P53-R/R72 groups,
respectively (pZ 0.046). The association of p53 genotypes
and breast cancer clinicopathologic features is inconsis-
tent. Previous studies reported that the p53-P/P72 homo-
zygotes seemed to present more often with lobular
carcinoma and grade 1 tumors [26] , that they were more
likely to have a positive axillary lymph node status [29], and
that they were significantly associated with ER-positive
breast cancer risk in postmenopausal women [31]. The
reason that p53-P/R72 genotypes are associated with
specific clinicopathologic features of breast cancer is
currently unknown. Although some studies supported the
finding that the P53-R72 allele represents a significant risk
in tumorigenesis [13e17], it has been reported that
patients with the p53-72P allele are more susceptible to
cancer development and a poor clinical outcome [26].
Recently, Ozeki et al. [32] demonstrated a novel molecular
difference underlying the tumor-suppressing function of
the P53-P/R72 variants and this may at least partiallyTable 2 The distribution of p53 genotypes in Asian and Caucas
p53-P/P72 (%) p53-R/P72 (%) p
Caucasian
Papadakis et al. [22] 12 (21) 10 (18)
Langerød et al. [38] 26 (6.7) 136 (34.9)
Bonafe et al. [25] 6 (8.9) 29 (43.3)
Suspitsin et al. [24] 39 (9) 169 (38)
Tommiska et al. [26] 63 (7.3) 336 (39.2)
Kalemi et al. [35] 3 (7) 13 (31)
Wegman et al. [39] 17 (7.7) 77 (35)
Schmidt et al. [40] 618 (7.4) 3228 (32.7)
Subtotal 784 (7.5) 3998 (38.3)
Asia
Tsai et al.[30] 36 (18) 100 (50.0)
Noma et al. [31] 29 (15.2) 69 (36.1)
Xu [29] 23 (21) 55 (50)
Ma [37] 77 (19.1) 178 (44.1)
Chen 31 (18.2) 93 (54.7)
Subtotal 194 (18) 485 (45.2)
a Arginine allele is an independent prognostic factor for disease free
b p53eP/P72 homozygote was an independent poor prognostic fa
p Z 0.001).
c Odds ratio for p53-R72 homozygotes to non- p53-R72 homozygote
d One p53-P72 allele had better distant recurrence-free survival wh
(p Z 0.0033).
e Significantly increased risk for p53-P72 homozygotes (odds ratio Z
f p53-P72 homozygotes were significantly associated with estrogen
(adjusted odds ratio Z 3.42, p < 0.01).
g p53-P72 homozygotes have more positive axillary lymph node stat
h p53-P72 homozygotes to be a strong predictor of poor patholog
confidence interval,1.4e31.2; p Z 0.016).
i BP1 genotypes of T-885G and Gln1136Lys were associated with
homozygotes.explain why p53-R72 is associated with smaller tumors.
They showed significantly diminished Mdm2-mediated
degradation of p53-72R compared with p53-P72, which is
associated with higher levels of phosphorylation at Ser-20 in
p53-R72. They also showed enhanced p21 expression in p53-
R72-expressing cells, which is dependent on phosphoryla-
tion at Ser-6 [32].
Although it has been proposed that there are inherent
differences in the relative prevalence of the polymorphism
in various populations [17,33], it is interesting to find
a discrepancy in the distributions of the p53 codon 72
polymorphism between Asian and Caucasian populations
(Table 2). There was more p53-P72 allele (40.6% in Asians
vs. 26.4% in Caucasians) and there was twice the incidence
of p53-P/P72 homozygotes (18% vs. 8%) among the Asian
population. The homogeneity of the incidence of each
genotype among different areas of Asia suggests consis-
tency in this result. Compatible with the p53 R72P poly-
morphism locating at the proline-rich domain, which is
responsible for the growth suppression and apoptosis
activity, p53-P72 was less efficient in suppressing cell
transformation, slower to induce apoptosis [34], and less
efficient at binding and inactivating p73, which is a tumor
suppressor protein responsible for apoptosis [14]. The
reason for the greater prevalence of the p53-P72 allele inian populations.
53-R/R72 (%) Risk factors Prognostic
factors
Predictive
factors
34 (61) N/A
228 (58.4) N/A
32 (47.8) N/A ARa
240 (54) Against
459 (53.5) Against p53-P/P72b
26 (62) p53-R/R72c
128 (57) N/A P53-P72d
4499 (53.9) Against
5646 (54.1)
64 (32.0) p53-P/P72e
93 (48.7) p53-P/P72f p53-P/P72f
32 (29) N/A p53-P/P72g p53-P/P72h
149 (36.8) p53-P/P72i
46 (27.1)
396 (36.8)
survival (DFS) (p Z 0.039) and overall survival (OS) (pZ 0.032).
ctor (risk ratio of death, 2.1; 95% confidence interval,1.4e3.3;
was 6.66, p Z 0.0001 at 95% confidence interval 2.63e16.9.
en randomized to tamoxifen compared with those who were not
2.14; 95% confidence interval Z 1.21e3.79).
receptor-positive breast cancer risk in postmenopausal women
us (p Z 0.007).
ic response to neoadjuvant chemotherapy (odds ratio 6.7, 95%
a significantly increased risk of breast cancer among p53-P72
p53 codon 72 polymorphism 263Asian patients with breast cancer remains unclear. In
contrast to p53-R72 as a risk factor of breast cancer in
a Caucasian [17,35] or Jewish population [36], p53-P/P72
homozygotes seem to be significantly associated with Asian
breast cancer risk [23,31,37].Conclusion
Our study suggested that the p53 codon 72 polymorphism in
Taiwanese women is similar to that of the Asian population.
We also found that p53-R/R72 phenotype was associated
with smaller tumor. That the prevalence of the p53-P72
allele in Taiwan and Asia may elucidate the difference of
the peak of the age-specific incidence rate of breast cancer
in patients in Asian and Western countries warrants further
research. Our preliminary results also need to be confirmed
by a future study including a larger number of patients.Acknowledgments
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